Clinical trials: Plasmodium Vivax Malaria
Malaria, Vivax
Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
The aim of the present study is to investigate the efficacy, safety and tolerability of a therapeutic course of Eurartesim® in travellers who contracted malaria due to infection by P. vivax in endemic countries.
- Trial name
- NCT02110784
- Testing
- Eurartesim tablets
- Where
- 13 sites in France, Germany and 5 more
- Volunteers
- 27 people
- Sponsor
- Alfasigma S.p.A.
Malaria, Vivax
Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection
This is a randomized open-label trial to evaluate the efficacy of chloroquine (CQ) alone compared to chloroquine+primaquine (CQ+PQ) in the treatment of uncomplicated malaria caused by Plasmodium vivax infection in a endemic area…
- Trial name
- NCT02691910
- Testing
- Chloroquine, Primaquine
- Where
- 2 sites in Brazil
- Volunteers
- 204 people
- Sponsor
- Oswaldo Cruz Foundation
Plasmodium Vivax Infection
Ethiopia Antimalarial in Vivo Efficacy Study 2012
The investigators hypothesize that the addition of primaquine (PQ) to both artemether-lumefantrine (AL) and chloroquine (CQ) for the treatment of Plasmodium vivax infection will result in decreased chance of relapse by about 60%.
- Trial name
- NCT01680406
- Testing
- Artemether-lumefantrine combination, Primaquine, Chloroquine
- Where
- 2 sites in Ethiopia
- Volunteers
- 398 people
- Sponsor
- Centers for Disease Control and Prevention
Plasmodium Falciparum, Plasmodium Vivax
The Malaria Heart Disease Study
The Malaria Heart Disease Study is a prospective longitudinal cohort study of a random sample of approximately 1200 individuals from the state of Acre in Brazil.
- Conditions
- Plasmodium Falciparum, Plasmodium Vivax, Heart Diseases, Cardiovascular Diseases
- Trial name
- NCT04445103
- Testing
- Assessment of cardiac function
- Where
- Brazil
- Volunteers
- 597 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Malaria, Vivax
Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria
Tafenoquine (TQ) is an 8-aminoquinoline anti-malarial drug which is in development as a single-dose treatment for the radical cure of P.vivax malaria when given with standard doses of chloroquine.
- Trial name
- NCT02802501
- Testing
- Tafenoquine, Primaquine, Dihydroartemisinin-piperaquine (DHA-PQP)
- Where
- Indonesia
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Malaria
MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria
The present proof-of-concept Phase IIa study aims to confirm, in patients, the observed activity of MMV390048 against P. falciparum in pre-clinical models and the human Induced Blood-Stage Malaria (IBSM) challenge model, and to…
- Trial name
- NCT02880241
- Testing
- MMV390048
- Where
- 2 sites in Ethiopia
- Volunteers
- 8 people
- Sponsor
- Medicines for Malaria Venture
Malaria
Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400 mg/day (Part 1) and single dosing with KAF156 at…
- Trial name
- NCT01753323
- Testing
- KAF156
- Where
- 5 sites in Thailand, Vietnam
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax
This will be a Proof-of-concept / Phase IIa, open label study to examine the efficacy of DSM265 in uncomplicated Plasmodium vivax and Plasmodium falciparum blood-stage malaria in adult patients.
- Trial name
- NCT02123290
- Testing
- DSM265 400mg, DSM265 xmg, DSM265 ymg
- Where
- Peru
- Volunteers
- 45 people
- Sponsor
- Medicines for Malaria Venture
Plasmodium Vivax Infection, Malaria Vaccine
A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
This project is the third part of a 5-year research program entitled "Malaria Infection Studies in Thailand (MIST)" and known as MIST3.
- Trial name
- MIST3 (NCT05380388)
- Testing
- Malaria Vaccine, HBV vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea
Malaria cases are increasing in Papua New Guinea, partly because insecticide-treated nets do not fully protect people, especially from mosquitoes that bite outdoors.
- Trial name
- WinMal (NCT07912528)
- Testing
- Spatial emanator outdoor, Spatial emanator indoor
- Where
- Papua New Guinea
- Volunteers
- 4,350 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria, Plasmodium Vivax
Phase Ia Study of ChAd63/MVA PvDBP
This is an open label phase Ia study, to assess the safety of two novel malaria vaccines, ChAd63 PvDBP, with or without MVA PvDBP.
- Trial name
- NCT01816113
- Testing
- ChAd63 PvDBP 5 x 10^9, ChAd63 PvDBP 5 x 10^10, MVA PvDBP 1 x 10^8
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax
Phenotyping and Genotyping of Duffy Antigen
Malaria remains the world's leading parasitic endemic. Almost half of the world's population lives in endemic areas. Many at-risk people in African countries remain without access to malaria control.
- Trial name
- DARC (NCT05527119)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Falciparum Malaria, Vivax Malaria
A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.
This open randomized, parallel group, 6 week trial in two rural outpatient clinics will compare the safety and efficacy of a six dose coartemether regimen with 3 dose artekin regimen for the treatment of acute, uncomplicated…
- Trial name
- NCT00157833
- Testing
- Artekin / Coartemther
- Where
- Indonesia
- Volunteers
- 750 people
- Sponsor
- Menzies School of Health Research
Efficacy, Malaria
Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax
The goal of this open label clinical trial will be to assess the therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax in Shecha Health Center, South Ethiopia.
- Conditions
- Efficacy, Malaria, Chloroquine, Vivax Malaria
- Trial name
- CQ+PQ (NCT06044805)
- Testing
- Chloroquine, Primaquine
- Where
- Ethiopia
- Volunteers
- 100 people
- Sponsor
- Dinka Dugassa
Malaria
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Part A -Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops.
- Trial name
- DSMOZ-2 (NCT02573857)
- Testing
- DSM265, OZ439
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Vivax
Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)
The study aims to provide evidence of retinal safety to support the use of tafenoquine as a potential single dose radical cure treatment for patients with Plasmodium vivax (P.
- Trial name
- NCT02658435
- Testing
- Tafenoquine 150 mg
- Where
- 3 sites in United States
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites
It is possible to safely protect human volunteers immunized with P. vivax irradiated sporozoites from P. vivax challenge with live sporozoites.
- Trial name
- SPZ-Irrad (NCT01082341)
- Testing
- Immunization with P. vivax irradiated sporozoites
- Where
- Colombia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria, Vivax, Relapse
Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia
Primaquine (PQ) is the only widely available treatment to prevent P. vivax relapses. World Health Organization recommends increased PQ doses in East Asia and Oceania, frequently relapsing strains.
- Trial name
- NCT05232227
- Testing
- Primaquine double dose over 14 days, Primaquine single dose over 14 days
- Sponsor
- University of California, San Francisco
Plasmodium Vivax
Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection
This study specifically seeks to provide data on the safety, tolerability and pilot efficacy of short course, high dose primaquine treatment in Papua New Guinean children aged 5-10 years, in a cross-sectional study design.
- Trial name
- NCT02364583
- Testing
- Primaquine
- Where
- Papua New Guinea
- Volunteers
- 150 people
- Sponsor
- Papua New Guinea Institute of Medical Research
Plasmodium Vivax Malaria, Malaria
FocaL Mass Drug Administration for Vivax Malaria Elimination
FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru.
- Trial name
- FLAME (NCT05690841)
- Testing
- Focal Mass Drug Administration (fMDA)
- Where
- Peru
- Volunteers
- 7,530 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco